Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 7849108, 14 pages
https://doi.org/10.1155/2017/7849108
Review Article

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host

Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Correspondence should be addressed to Tiziana Triulzi; ti.im.iromutotutitsi@izluirt.anaizit

Received 25 August 2017; Accepted 21 November 2017; Published 18 December 2017

Academic Editor: Paul Span

Copyright © 2017 Martina Di Modica et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB signalling network,” Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127–137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Ménard, S. M. Pupa, M. Campiglio, and E. Tagliabue, “Biologic and therapeutic role of HER2 in cancer,” Oncogene, vol. 22, no. 42, pp. 6570–6578, 2003. View at Publisher · View at Google Scholar
  3. R. H. Engel and V. G. Kaklamani, “HER2-positive breast cancer: current and future treatment strategies,” Drugs, vol. 67, no. 9, pp. 1329–1341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Dawood, K. Broglio, A. U. Buzdar, G. N. Hortobagyi, and S. H. Giordano, “Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 92–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Callahan and S. Hurvitz, “Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease,” Current Opinion in Obstetrics and Gynecology, vol. 23, no. 1, pp. 37–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. L. Spector and K. L. Blackwell, “Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5838–5847, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Tagliabue, M. Campiglio, S. M. Pupa, A. Balsari, and S. Ménard, “The HER2 world: better treatment selection for better outcome,” JNCI Monographs, vol. 2011, no. 43, pp. 82–85, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. H. A. Lane, I. Beuvink, A. B. Motoyama, J. M. Daly, R. M. Neve, and N. E. Hynes, “ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency,” Molecular and Cellular Biology, vol. 20, no. 9, pp. 3210–3223, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. J. C. Sarup, R. M. Johnson, K. L. King et al., “Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth,” Growth Regulation, vol. 1, no. 2, pp. 72–82, 1991. View at Google Scholar
  10. H. J. Burstein, L. N. Harris, R. Gelman et al., “Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 46–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga, “Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells,” Cancer Research, vol. 61, no. 12, pp. 4744–4749, 2001. View at Google Scholar
  12. A. Schneeweiss, S. Chia, R. Hegg et al., “Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study,” Breast Cancer Research, vol. 16, no. 4, article R73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Bianchini, A. Kiermaier, G. V. Bianchi et al., “Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer,” Breast Cancer Research, vol. 19, no. 1, p. 16, 2017. View at Publisher · View at Google Scholar
  14. Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, and R. K. Jain, “Tumour biology: herceptin acts as an anti-angiogenic cocktail,” Nature, vol. 416, no. 6878, pp. 279-280, 2002. View at Publisher · View at Google Scholar
  15. R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine, vol. 6, no. 4, pp. 443–446, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Musolino, N. Naldi, B. Bortesi et al., “Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu–positive metastatic breast cancer,” Journal of Clinical Oncology, vol. 26, no. 11, pp. 1789–1796, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Tamura, C. Shimizu, T. Hojo et al., “FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer,” Annals of Oncology, vol. 22, no. 6, pp. 1302–1307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Gennari, S. Ménard, F. Fagnoni et al., “Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2,” Clinical Cancer Research, vol. 10, no. 17, pp. 5650–5655, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Arnould, M. Gelly, F. Penault-Llorca et al., “Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?” British Journal of Cancer, vol. 94, no. 2, pp. 259–267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Varchetta, N. Gibelli, B. Oliviero et al., “Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2,” Cancer Research, vol. 67, no. 24, pp. 11991–11999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Di Modica, L. Sfondrini, V. Regondi et al., “Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition,” Oncotarget, vol. 7, no. 1, pp. 255–265, 2016. View at Publisher · View at Google Scholar
  22. A. U. Buzdar, V. Valero, N. K. Ibrahim et al., “Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2–positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen,” Clinical Cancer Research, vol. 13, no. 1, pp. 228–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. R. Campbell, M. C. Duggan, L. P. Suarez-Kelly et al., “MICA-expressing monocytes enhance natural killer cell Fc receptor-mediated antitumor functions,” Cancer Immunology Research, vol. 5, no. 9, pp. 778–789, 2017. View at Publisher · View at Google Scholar
  24. Y. Shi, X. Fan, H. Deng et al., “Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages,” The Journal of Immunology, vol. 194, no. 9, pp. 4379–4386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Stagg, S. Loi, U. Divisekera et al., “Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 17, pp. 7142–7147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. S. G. Park, Z. Jiang, E. D. Mortenson et al., “The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity,” Cancer Cell, vol. 18, no. 2, pp. 160–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. E. D. Mortenson, S. Park, Z. Jiang, S. Wang, and Y. X. Fu, “Effective anti-neu–initiated antitumor responses require the complex role of CD4+ T cells,” Clinical Cancer Research, vol. 19, no. 6, pp. 1476–1486, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. V. A. Gall, A. V. Philips, N. Qiao et al., “Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells,” Cancer Research, vol. 77, no. 19, pp. 5374–5383, 2017. View at Publisher · View at Google Scholar
  29. R. Charlebois, B. Allard, D. Allard et al., “PolyI:C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors,” Cancer Research, vol. 77, no. 2, pp. 312–319, 2017. View at Publisher · View at Google Scholar
  30. H. Lu, Y. Yang, E. Gad et al., “TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy,” Clinical Cancer Research, vol. 17, no. 21, pp. 6742–6753, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Datta, S. Xu, C. Rosemblit et al., “CD4+ T-helper type 1 cytokines and trastuzumab facilitate CD8+ T-cell targeting of HER2/neu–expressing cancers,” Cancer Immunology Research, vol. 3, no. 5, pp. 455–463, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Datta, E. Berk, S. Xu et al., “Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer,” Breast Cancer Research, vol. 17, no. 1, p. 71, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Mittal, F. Caramia, S. Michiels et al., “Improved treatment of breast cancer with anti-HER2 therapy requires interleukin-21 signaling in CD8+ T cells,” Cancer Research, vol. 76, no. 2, pp. 264–274, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Xu, M. Liu, X. Du et al., “Intratumoral delivery of IL-21 overcomes anti-Her2/neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype,” The Journal of Immunology, vol. 194, no. 10, pp. 4997–5006, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Taylor, D. Hershman, N. Shah et al., “Augmented HER-2–specific immunity during treatment with trastuzumab and chemotherapy,” Clinical Cancer Research, vol. 13, no. 17, pp. 5133–5143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. K. L. Knutson, R. Clynes, B. Shreeder et al., “Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain,” Cancer Research, vol. 76, no. 13, pp. 3702–3710, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Capelan, L. Pugliano, E. De Azambuja et al., “Pertuzumab: new hope for patients with HER2-positive breast cancer,” Annals of Oncology, vol. 24, no. 2, pp. 273–282, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. D. B. Agus, R. W. Akita, W. D. Fox et al., “Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth,” Cancer Cell, vol. 2, no. 2, pp. 127–137, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. A. H. Sims, A. J. M. Zweemer, Y. Nagumo et al., “Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer,” British Journal of Cancer, vol. 106, no. 11, pp. 1779–1789, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Scheuer, T. Friess, H. Burtscher, B. Bossenmaier, J. Endl, and M. Hasmann, “Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models,” Cancer Research, vol. 69, no. 24, pp. 9330–9336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Nahta, M. C. Hung, and F. J. Esteva, “The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells,” Cancer Research, vol. 64, no. 7, pp. 2343–2346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Toth, A. Szoor, L. Simon, Y. Yarden, J. Szollosi, and G. Vereb, “The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity,” mAbs, vol. 8, no. 7, pp. 1361–1370, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Mamidi, M. Cinci, M. Hasmann, V. Fehring, and M. Kirschfink, “Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab,” Molecular Oncology, vol. 7, no. 3, pp. 580–594, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. C. I. Spiridon, M. A. Ghetie, J. Uhr et al., “Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo,” Clinical Cancer Research, vol. 8, no. 6, pp. 1720–1730, 2002. View at Google Scholar
  45. R. Schroeder, C. Stevens, and J. Sridhar, “Small molecule tyrosine kinase inhibitors of ErbB2/HER2/neu in the treatment of aggressive breast cancer,” Molecules, vol. 19, no. 9, pp. 15196–15212, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. D. W. Rusnak, K. Lackey, K. Affleck et al., “The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 1, no. 2, pp. 85–94, 2001. View at Google Scholar
  47. G. E. Konecny, M. D. Pegram, N. Venkatesan et al., “Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells,” Cancer Research, vol. 66, no. 3, pp. 1630–1639, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. K. K. Shiu, D. Wetterskog, A. Mackay et al., “Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies,” Oncogene, vol. 33, no. 5, pp. 619–631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Li and N. D. Marchenko, “ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells,” Oncotarget, vol. 8, no. 4, pp. 5823–5833, 2017. View at Publisher · View at Google Scholar
  50. T. Yu, B. J. Cho, E. J. Choi, J. M. Park, D. H. Kim, and I. A. Kim, “Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells,” Oncotarget, vol. 7, no. 48, pp. 79089–79100, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Chu, K. Blackwell, S. Chen, and J. Slingerland, “The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer,” Cancer Research, vol. 65, no. 1, pp. 18–25, 2005. View at Google Scholar
  52. M. Scaltriti, C. Verma, M. Guzman et al., “Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity,” Oncogene, vol. 28, no. 6, pp. 803–814, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Maruyama, K. Mimura, S. Izawa et al., “Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression,” Anticancer Research, vol. 31, no. 9, pp. 2999–3005, 2011. View at Google Scholar
  54. L. Hannesdóttir, P. Tymoszuk, N. Parajuli et al., “Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response,” European Journal of Immunology, vol. 43, no. 10, pp. 2718–2729, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Wissner and T. S. Mansour, “The development of HKI-272 and related compounds for the treatment of cancer,” Archiv der Pharmazie, vol. 341, no. 8, pp. 465–477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. S. K. Rabindran, C. M. Discafani, E. C. Rosfjord et al., “Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase,” Cancer Research, vol. 64, no. 11, pp. 3958–3965, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Canonici, M. Gijsen, M. Mullooly et al., “Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer,” Oncotarget, vol. 4, no. 10, pp. 1592–1605, 2013. View at Publisher · View at Google Scholar
  58. D. M. Collins, K. Gately, C. Hughes et al., “Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines,” Cellular Immunology, vol. 319, pp. 35–42, 2017. View at Publisher · View at Google Scholar
  59. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Gianni, W. Eiermann, V. Semiglazov et al., “Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort,” Lancet, vol. 375, no. 9712, pp. 377–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Untch, M. Rezai, S. Loibl et al., “Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 2024–2031, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Valachis, D. Mauri, N. P. Polyzos, G. Chlouverakis, D. Mavroudis, and V. Georgoulias, “Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis,” Breast, vol. 20, no. 6, pp. 485–490, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. G. von Minckwitz, M. Untch, E. Nüesch et al., “Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials,” Breast Cancer Research and Treatment, vol. 125, no. 1, pp. 145–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Natoli, P. Vici, I. Sperduti et al., “Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 7, pp. 1229–1240, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Goldhirsch, M. J. Piccart-Gebhart, M. Procter et al., “Abstract S5-2: HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up,” Cancer Research, vol. 72, Supplement 24, 2013. View at Publisher · View at Google Scholar
  66. H. Joensuu, P. Bono, V. Kataja et al., “Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5685–5692, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. E. A. Perez, E. H. Romond, V. J. Suman et al., “Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31,” Journal of Clinical Oncology, vol. 29, no. 25, pp. 3366–3373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thurlimann, and H. J. Senn, “Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011,” Annals of Oncology, vol. 22, no. 8, pp. 1736–1747, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Slamon, W. Eiermann, N. Robert et al., “Adjuvant trastuzumab in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 365, no. 14, pp. 1273–1283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. I. J. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, and S. Murray, “Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials,” The Oncologist, vol. 13, no. 6, pp. 620–630, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. S. C. Seferina, D. J. A. Lobbezoo, M. de Boer et al., “Real-life use and effectiveness of adjuvant trastuzumab in early breast cancer patients: a study of the Southeast Netherlands breast cancer consortium,” The Oncologist, vol. 20, no. 8, pp. 856–863, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Campiglio, R. Bufalino, M. Sasso et al., “Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study,” Breast Cancer Research and Treatment, vol. 141, no. 1, pp. 101–110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Matos, B. Zakotnik, and C. G. Kuhar, “Effectiveness of adjuvant trastuzumab in daily clinical practice,” Radiology and Oncology, vol. 48, no. 4, pp. 403–407, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Baselga, J. Cortés, S. B. Kim et al., “Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer,” The New England Journal of Medicine, vol. 366, no. 2, pp. 109–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Amiri-Kordestani, S. Wedam, L. Zhang et al., “First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer,” Clinical Cancer Research, vol. 20, no. 21, pp. 5359–5364, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Gianni, T. Pienkowski, Y. H. Im et al., “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 1, pp. 25–32, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Schneeweiss, S. Chia, T. Hickish et al., “Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA),” Annals of Oncology, vol. 24, no. 9, pp. 2278–2284, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Von Minckwitz, M. Procter, E. De Azambuja et al., “Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer,” The New England Journal of Medicine, vol. 377, no. 2, pp. 122–131, 2017. View at Publisher · View at Google Scholar
  79. C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Jiang and H. S. Rugo, “Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options,” Therapeutic Advances in Medical Oncology, vol. 7, no. 6, pp. 321–339, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Baselga, I. Bradbury, H. Eidtmann et al., “Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial,” Lancet, vol. 379, no. 9816, pp. 633–640, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. V. Guarneri, A. Frassoldati, A. Bottini et al., “Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2–positive operable breast cancer: results of the randomized phase II CHER-LOB study,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1989–1995, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Robidoux, G. Tang, P. Rastogi et al., “Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 14, no. 12, pp. 1183–1192, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. L. A. Carey, D. A. Berry, D. Ollila et al., “Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer,” Journal of Clinical Oncology, vol. 31, Supplement 15, 2013. View at Google Scholar
  85. A. Valachis, A. Nearchou, P. Lind, and D. Mauri, “Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence,” Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 655–662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. M. J. Piccart-Gebhart, A. P. Holmes, J. Baselga et al., “First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC),” Journal of Clinical Oncology, vol. 32, 15 Supplement, 2014. View at Google Scholar
  87. I. Echavarria, S. Lopez-Tarruella, I. Marquez-Rodas, Y. Jerez, and M. Martin, “Neratinib for the treatment of HER2-positive early stage breast cancer,” Expert Review of Anticancer Therapy, vol. 17, no. 8, pp. 669–679, 2017. View at Publisher · View at Google Scholar
  88. J. W. Park, M. C. Liu, D. Yee et al., “Adaptive randomization of neratinib in early breast cancer,” The New England Journal of Medicine, vol. 375, no. 1, pp. 11–22, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. “Neratinib Approved for HER2+ Breast Cancer,” Cancer Discovery, vol. 7, no. 9, 2017. View at Publisher · View at Google Scholar
  90. A. Chan, S. Delaloge, F. A. Holmes et al., “Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 17, no. 3, pp. 367–377, 2016. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Triulzi, G. V. Bianchi, and E. Tagliabue, “Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge,” Future Oncology, vol. 12, no. 11, pp. 1413–1428, 2016. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Prat, L. A. Carey, B. Adamo et al., “Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer,” Journal of the National Cancer Institute, vol. 106, no. 8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours,” Nature, vol. 490, no. 7418, pp. 61–70, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Prat, G. Bianchini, M. Thomas et al., “Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study,” Clinical Cancer Research, vol. 20, no. 2, pp. 511–521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Fumagalli, D. Venet, M. Ignatiadis et al., “RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial,” JAMA Oncology, vol. 3, no. 2, p. 227, 2016. View at Publisher · View at Google Scholar
  96. M. V. Dieci, A. Prat, E. Tagliafico et al., “Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial,” Annals of Oncology, vol. 27, no. 10, pp. 1867–1873, 2016. View at Publisher · View at Google Scholar
  97. K. L. Pogue-Geile, N. Song, J. H. Jeong et al., “Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial,” Journal of Clinical Oncology, vol. 33, no. 12, pp. 1340–1347, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. E. A. Perez, K. V. Ballman, A. Mashadi-Hossein et al., “Intrinsic subtype and therapeutic response among HER2-positive breast tumors from the NCCTG (Alliance) N9831 trial,” Journal of the National Cancer Institute, vol. 109, no. 2, article djw207, 2017. View at Publisher · View at Google Scholar
  99. K. L. Pogue-Geile, C. Kim, J. H. Jeong et al., “Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31,” Journal of the National Cancer Institute, vol. 105, no. 23, pp. 1782–1788, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. T. Triulzi, L. De Cecco, M. Sandri et al., “Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration,” Oncotarget, vol. 6, no. 29, pp. 28173–28182, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Denkert, J. Huober, S. Loibl et al., “HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer,” Breast Cancer Research, vol. 15, no. 1, article R11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Llombart-Cussac, J. Cortés, L. Paré et al., “HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial,” The Lancet Oncology, vol. 18, no. 4, pp. 545–554, 2017. View at Publisher · View at Google Scholar
  103. E. A. Perez, E. A. Thompson, K. V. Ballman et al., “Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 adjuvant trastuzumab trial,” Journal of Clinical Oncology, vol. 33, no. 7, pp. 701–708, 2015. View at Publisher · View at Google Scholar · View at Scopus
  104. G. Bianchini, L. Pusztai, T. Pienkowski et al., “Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial,” Annals of Oncology, vol. 26, no. 12, pp. 2429–2436, 2015. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Salgado, C. Denkert, C. Campbell et al., “Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial,” JAMA Oncology, vol. 1, no. 4, pp. 448–454, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Untch, S. Loibl, J. Bischoff et al., “Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial,” The Lancet Oncology, vol. 13, no. 2, pp. 135–144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. B. Ingold Heppner, M. Untch, C. Denkert et al., “Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer,” Clinical Cancer Research, vol. 22, no. 23, pp. 5747–5754, 2016. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Loi, S. Michiels, R. Salgado et al., “Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial,” Annals of Oncology, vol. 25, no. 8, pp. 1544–1550, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. E. A. Perez, K. V. Ballman, K. S. Tenner et al., “Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer,” JAMA Oncology, vol. 2, no. 1, pp. 56–64, 2016. View at Publisher · View at Google Scholar
  110. P. G. Gavin, N. Song, S. R. Kim, K. L. Pogue-Geile, and S. Paik, “Immune signature to predict trastuzumab benefit: potential and pitfalls,” Journal of Clinical Oncology, vol. 33, no. 31, pp. 3671-3672, 2015. View at Publisher · View at Google Scholar · View at Scopus
  111. V. Varadan, H. Gilmore, K. L. S. Miskimen et al., “Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer,” Clinical Cancer Research, vol. 22, no. 13, pp. 3249–3259, 2016. View at Publisher · View at Google Scholar · View at Scopus
  112. R. Salgado, C. Denkert, S. Demaria et al., “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014,” Annals of Oncology, vol. 26, no. 2, pp. 259–271, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Hendry, R. Salgado, T. Gevaert et al., “Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group,” Advances in Anatomic Pathology, vol. 24, no. 5, pp. 235–251, 2017. View at Publisher · View at Google Scholar
  114. P. Savas, R. Salgado, C. Denkert et al., “Clinical relevance of host immunity in breast cancer: from TILs to the clinic,” Nature Reviews Clinical Oncology, vol. 13, no. 4, pp. 228–241, 2016. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Spranger, J. J. Luke, R. Bao et al., “Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 48, pp. E7759–E7768, 2016. View at Publisher · View at Google Scholar · View at Scopus
  116. P. S. Savas, R. Salgado, F. Caramia et al., “Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC),” Journal of Clinical Oncology, vol. 33, Supplement 15, 2015. View at Google Scholar
  117. M. G. Borrello, L. Alberti, A. Fischer et al., “Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 41, pp. 14825–14830, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. E. Tagliabue, L. Forte, V. Regondi, C. Ghirelli, P. Aiello, and T. Triulzi, “Abstract P4-21-33: HER2 activity regulates the pro-trastuzumab immune tumor microenvironment,” Cancer Research, vol. 77, Supplement 4, 2017. View at Publisher · View at Google Scholar
  120. A. Safonov, T. Jiang, G. Bianchini et al., “Immune gene expression is associated with genomic aberrations in breast cancer,” Cancer Research, vol. 77, no. 12, pp. 3317–3324, 2017. View at Publisher · View at Google Scholar
  121. J. S. Brown, R. Sundar, and J. Lopez, “Combining DNA damaging therapeutics with immunotherapy: more haste, less speed,” British Journal of Cancer, 2017. View at Publisher · View at Google Scholar
  122. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer, “Immunological aspects of cancer chemotherapy,” Nature Reviews Immunology, vol. 8, no. 1, pp. 59–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. L. Pusztai, T. Karn, A. Safonov, M. M. Abu-Khalaf, and G. Bianchini, “New strategies in breast cancer: immunotherapy,” Clinical Cancer Research, vol. 22, no. 9, pp. 2105–2110, 2016. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Turcotte, D. Allard, D. Mittal et al., “CD73 promotes resistance to HER2/ErbB2 antibody therapy,” Cancer Research, vol. 77, no. 20, pp. 5652–5663, 2017. View at Publisher · View at Google Scholar